Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy.

Autor: Franceschini D; IRCCS Humanitas Research Hospital, Milan, Italy., Polenghi V; MOX lab, Department of Mathematics, Politecnico di Milano, Milano, Italia., Franzese C; IRCCS Humanitas Research Hospital, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Comito T; IRCCS Humanitas Research Hospital, Milan, Italy., Navarria P; IRCCS Humanitas Research Hospital, Milan, Italy., D'Agostino GR; IRCCS Humanitas Research Hospital, Milan, Italy., Ieva F; MOX lab, Department of Mathematics, Politecnico di Milano, Milano, Italia.; CADS - Center for Analysis, Decisions and Society, Human Technopole, Milan, Italy., Scorsetti M; IRCCS Humanitas Research Hospital, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Jazyk: angličtina
Zdroj: Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2022 May; Vol. 61 (5), pp. 553-559. Date of Electronic Publication: 2022 Feb 24.
DOI: 10.1080/0284186X.2022.2042475
Abstrakt: Background: to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT).
Material and Methods: Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score.
Results: 997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group.
Conclusion: moving from easily accessible clinical parameters, a score was created to help the physician's decision about the better treatment or combination of treatments for the individual patient.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje